Company Filing History:
2 out of 1,193 
1 out of 8 
1 out of 13 
Years Active: 2012-2013
Title: The Innovative Contributions of John A. McLachlan in Cancer Research
Introduction
John A. McLachlan, an esteemed inventor based in New Orleans, LA, has made significant strides in the field of cancer research through his innovative work. With two patents to his name, his contributions focus on synthesizing glyceollins, which are phytoalexin compounds derived from soy, showcasing their therapeutic potentials in treating cancer.
Latest Patents
McLachlan’s latest patents detail two unique methods for synthesizing glyceollin I and glyceollin II, both as mixtures and pure forms. These patents encompass the synthesis of stereochemical isomers and various synthetic intermediates, all claimed for their novel compositions. The compounds are particularly noted for their potential use in formulations designed to treat or prevent cancer. McLachlan’s work highlights their utility as selective estrogen receptor modulators, which are vital in creating enhanced medical foods, dietary supplements, and ethical pharmaceutical agents. Importantly, glyceollins exhibit anti-estrogenic properties that can suppress the proliferation and tumorigenesis of human breast and ovarian carcinoma cells.
Career Highlights
Throughout his career, McLachlan has focused on the relationship between soy-derived flavonoids and their effects on human health. His research has identified that the biosynthesis of glyceollins is augmented in soy plants subjected to stress, suggesting potential health benefits based on the presence of these hormonally active compounds. His innovative methodologies have positioned him as a leading voice in the development of novel anti-estrogens with the potential to prevent or treat breast and ovarian cancer.
Collaborations
John A. McLachlan has collaborated with prominent professionals in his field, including Thomas E. Cleveland and Stephen M. Boue. Additionally, he has worked with renowned institutions such as the United States Department of Agriculture and the Tulane Educational Fund, underscoring his commitment to advancing scientific research in cancer treatment.
Conclusion
John A. McLachlan’s innovative contributions continue to have a profound impact on cancer research, highlighting the importance of natural compounds in therapeutic applications. As the understanding of glyceollins and their effects on estrogen-sensitive tumors progresses, McLachlan’s findings promise to enhance treatment options for breast and ovarian carcinomas. His work exemplifies the power of innovation in addressing significant health challenges.